Umeå University's logo

Lymphomas represent a biologically diverse group of B-, T-, and NK-cell malig-nancies, where challenges such as relapse, drug resistance, treatment-relatedtoxicity, sanctuary-site disease, and variable antigen expression continue toimpede therapeutic outcomes, despite significant advancements in immunother-apy. Nanomedicine presents a strategic approach to enhance drug delivery, targetmalignant lymphocytes or supportive microenvironmental cells, and integratemolecular imaging with therapy; however, the extent of clinical validation variesconsiderably across different platforms. This review provides an overview ofnanotechnology-enabled strategies for the treatment of lymphoma, includingantibody–drug and radioimmunoconjugates, liposomal and albumin-based drugcarriers, aptamer-guided systems, photothermal and photodynamic platforms,exosomes and liquid-biopsy nanoprobes, mRNA/lipid nanoparticle strategies,and AI-guided design. We highlight lymphoma-specific delivery challenges, suchas the presence of bulky nodal disease, circulating malignant cells, marrow andCNS involvement, splenic and hepatic sequestration, antigen sinks, and the lim-ited reliability of passive enhanced permeability and retention. Approved andguideline-supported examples are differentiated from active clinical trials and preclinical-only concepts to provide a clinically oriented interpretation of thecurrent evidence and future translational priorities.